Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often the only potentially curative treatment option in patients with different hematologic malignancies, non-malignant disorders like severe aplastic anaemia, and some types of inborn errors of immunity. The main goals of allo-HSCT are graft versus malignancy effect, restoring normal hematopoiesis and re-establishing immune system function. Before an every allotransplant procedure the special preparative regimen, called conditioning, is used. These conditioning protocols are based on chemotherapy/radiotherapy and immunosuppressive treatment for limiting the risk of graft rejection and prophylaxis of graft versus host disease. The toxicity of preparative regimens is still an issue in allo-HSCT recipients leading to serious, sometimes life-threatening early and late complications. Primary disease relapses and infectious and non-infectious complications after allo-HSCT procedures remain a major challenge in a short- and long-term care of this group of patients.
In this Allo-HSCT article collection, we would like to focus on rare early and late complications after different types of allogeneic stem cell transplantation in hematological malignancy and non-malignant diseases. Furthermore we are interested in novel strategies in utilization new conditioning regimens in various indications for allogeneic stem cell transplantation, for example in inborn errors of immunity in adults, in severe aplastic anaemia in older recipients, in primary refractory or relapsed acute leukemias. This is mainly clinical project, but basic research covering presented topics are welcoming, too. We are expecting various kinds of submissions: original research, review articles, case series with discussing and analysis of presented subject that address and include but are not limited to the following aspects:
1. Treosulfan-based conditioning regimen in allo-HSCT in adult patients with inborn errors of immunity and rare disorders.
2. “Up-front” allogeneic stem cell transplantation in elderly patients with SAA/vSAA.
3. “Up-front” haplo-HSCT with PTCy in patients with SAA/vSAA.
4. Lyell’s syndrome after allogeneic stem cell transplantation in adults
5. Prevalence of an early (until +60 day) Post-Transplant Lymphoproliferative Disorders after allogeneic stem cell transplantation.
6. Evaluation of methods of conditioning in relapsed/primary refractory acute myeloid leukemia before allogeneic stem cell transplantation.
7. Rare infectious complications after allogeneic stem cell transplantation.
Topic editor Agnieszka Tomaszewska received travel grants and lectures’ grants from Medac, Novartis, Gilead, Astra Zeneca. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords: Allogeneic hematopoietic stem cell transplantation, allo-HCT, inborn errors of immunity, allo-HSCT
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
